Understand the source comparison
Mechanism Comparison: Lipolytic Peptide Fragment vs GLP-1 Receptor Agonism
AOD-9604's structure replicates the C-terminal fragment of human growth hormone (amino acids 176–191), the region identified as responsible for HGH's fat-reducing effects without its insulin-antagonistic properties. Preclinical studies in rodents demonstrated
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AOD-9604's structure replicates the C-terminal fragment of human growth hormone (amino acids 176–191), the region identified as responsible for HGH's fat-reducing effects without its insulin-antagonistic properties. Preclinical studies in rodents demonstrated increased fatty acid oxidation and reduced body fat accumulation, but translating those findings to humans has proven inconsistent. The 2008 human trial used doses ranging from 1mg to 10mg daily subcutaneously for 12 weeks. None showed meaningful fat mass reduction compared to placebo.
- Wegovy operates through a well-characterised pathway: semaglutide binds to GLP-1 receptors with 94% homology to native human GLP-1, triggering intracellular signalling cascades that reduce food intake by 20–35% in clinical settings. The STEP-1 trial published in NEJM found that 2.4mg weekly semaglutide produced mean body weight reduction of 14.9% versus 2.4% with placebo at 68 weeks. A magnitude that lifestyle intervention alone rarely achieves. GI side effects (nausea, vomiting, diarrhoea) occur in 30–45% during dose titration but typically resolve within 4–8 weeks as GLP-1 receptor density in the gut downregulates.
- For researchers exploring alternatives, understanding these mechanistic differences is critical. AOD-9604 doesn't suppress appetite. It theoretically increases the rate at which adipocytes release stored triglycerides. Wegovy doesn't directly affect adipocyte metabolism. It reduces caloric intake by extending satiety signals. You can explore research-grade peptides designed for lipolytic investigation through our FAT Loss Metabolic Health Bundle, which includes compounds with complementary metabolic pathways.